



**THE JACKSON LABORATORY**

Financial Statements

December 31, 2016 and 2015

(With Independent Auditors' Report Thereon)



KPMG LLP  
Two Financial Center  
60 South Street  
Boston, MA 02111

## Independent Auditors' Report

The Board of Trustees  
The Jackson Laboratory:

We have audited the accompanying financial statements of The Jackson Laboratory (the Laboratory), which comprise the balance sheets as of December 31, 2016 and 2015, the related statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

### *Management's Responsibility for the Financial Statements*

Management is responsible for the preparation and fair presentation of these financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### *Auditors' Responsibility*

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### *Opinion*

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Jackson Laboratory as of December 31, 2016 and 2015, and the changes in its net assets and its cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.

**KPMG LLP**

Boston, Massachusetts  
May 12, 2017

**THE JACKSON LABORATORY**

Balance Sheets

December 31, 2016 and 2015

(Dollars in thousands)

<b>Assets</b>	<b>2016</b>	<b>2015</b>
Cash and equivalents	\$ 9,602	4,375
Working capital investments, at fair value	191,083	171,833
Funds held in escrow	—	326
Accounts receivable, net	32,739	32,988
Contributions receivable, net	5,838	6,067
Other assets	22,133	14,979
Long-term investments, at fair value	142,755	132,699
Long-lived assets, net	391,524	391,073
Total assets	\$ 795,674	754,340
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$ 38,336	41,022
Accrued postretirement obligations	6,321	5,659
Interest rate swaps, at fair value	5,463	6,454
Deposits and deferred revenue	10,562	7,157
Bonds and note payable, net	96,244	100,151
Connecticut forgivable loans, at fair value	5,760	7,270
Total liabilities	162,686	167,713
Net assets:		
Unrestricted	571,598	527,883
Temporarily restricted	41,210	40,348
Permanently restricted	20,180	18,396
Total net assets	632,988	586,627
Total liabilities and net assets	\$ 795,674	754,340

See accompanying notes to financial statements

**THE JACKSON LABORATORY**

Statement of Activities

Year ended December 31, 2016

(Dollars in thousands)

	<u>Unrestricted</u>	<u>Temporarily restricted</u>	<u>Permanently restricted</u>	<u>Total</u>
Operating activities:				
Revenue and other support:				
Grants	\$ 81,791	—	—	81,791
Contributions	1,309	918	—	2,227
Genetic resources and services	230,818	—	—	230,818
Long-term investment return utilized	366	614	—	980
Other investment return	7,874	—	—	7,874
Other revenue	3,309	—	—	3,309
Total revenue	<u>325,467</u>	<u>1,532</u>	<u>—</u>	<u>326,999</u>
Net assets released from restrictions	<u>1,713</u>	<u>(1,715)</u>	<u>2</u>	<u>—</u>
Total revenue and other support	<u>327,180</u>	<u>(183)</u>	<u>2</u>	<u>326,999</u>
Expenses:				
Research	108,045	—	—	108,045
Genetic resources and services	129,570	—	—	129,570
Training	7,588	—	—	7,588
Institutional support	55,105	—	—	55,105
Total expenses	<u>300,308</u>	<u>—</u>	<u>—</u>	<u>300,308</u>
Increase (decrease) in net assets from operating activities	<u>26,872</u>	<u>(183)</u>	<u>2</u>	<u>26,691</u>
Nonoperating activities:				
Grants and contributions for capital and long-term investments	2,280	19	1,782	4,081
Long-term investment return above amounts utilized	5,945	1,026	—	6,971
Unrealized net gain on interest-rate swaps	991	—	—	991
Adjustment to fair value of Connecticut forgivable loans	7,748	—	—	7,748
Other	(121)	—	—	(121)
Increase in net assets from nonoperating activities	<u>16,843</u>	<u>1,045</u>	<u>1,782</u>	<u>19,670</u>
Increase in net assets	43,715	862	1,784	46,361
Net assets, beginning of year	<u>527,883</u>	<u>40,348</u>	<u>18,396</u>	<u>586,627</u>
Net assets, end of year	<u>\$ 571,598</u>	<u>41,210</u>	<u>20,180</u>	<u>632,988</u>

See accompanying notes to financial statements.

**THE JACKSON LABORATORY**

Statement of Activities

Year ended December 31, 2015

(Dollars in thousands)

	<u>Unrestricted</u>	<u>Temporarily restricted</u>	<u>Permanently restricted</u>	<u>Total</u>
Operating activities:				
Revenue and other support:				
Grants	\$ 82,052	—	—	82,052
Contributions	1,147	3,377	—	4,524
Genetic resources and services	209,836	—	—	209,836
Long-term investment return utilized	—	548	—	548
Other investment return	801	—	—	801
Other revenue	<u>2,565</u>	<u>—</u>	<u>—</u>	<u>2,565</u>
Total revenue	296,401	3,925	—	300,326
Net assets released from restrictions	<u>1,736</u>	<u>(1,738)</u>	<u>2</u>	<u>—</u>
Total revenue and other support	<u>298,137</u>	<u>2,187</u>	<u>2</u>	<u>300,326</u>
Expenses:				
Research	102,407	—	—	102,407
Genetic resources and services	121,245	—	—	121,245
Training	5,958	—	—	5,958
Institutional support	<u>51,933</u>	<u>—</u>	<u>—</u>	<u>51,933</u>
Total expenses	<u>281,543</u>	<u>—</u>	<u>—</u>	<u>281,543</u>
Increase in net assets from operating activities	<u>16,594</u>	<u>2,187</u>	<u>2</u>	<u>18,783</u>
Nonoperating activities:				
Grants and contributions for capital and long-term investments	138	168	3,064	3,370
Long-term investment return above amounts utilized	(517)	(757)	—	(1,274)
Unrealized net gain on interest-rate swaps	355	—	—	355
Change in funded status of pension and post-retirement benefit plans	490	—	—	490
Adjustment to fair value of Connecticut forgivable loans	75,936	—	—	75,936
Other	<u>(4,143)</u>	<u>124</u>	<u>—</u>	<u>(4,019)</u>
Increase (decrease) in net assets from nonoperating activities	<u>72,259</u>	<u>(465)</u>	<u>3,064</u>	<u>74,858</u>
Increase in net assets	88,853	1,722	3,066	93,641
Net assets, beginning of year	<u>439,030</u>	<u>38,626</u>	<u>15,330</u>	<u>492,986</u>
Net assets, end of year	<u>\$ 527,883</u>	<u>40,348</u>	<u>18,396</u>	<u>586,627</u>

See accompanying notes to financial statements.

**THE JACKSON LABORATORY**

Statements of Cash Flows

Years ended December 31, 2016 and 2015

(Dollars in thousands)

	<u>2016</u>	<u>2015</u>
Cash flows from operating activities:		
Increase in net assets	\$ 46,361	93,641
Adjustments to reconcile increase in net assets to cash provided by operating activities:		
Depreciation and amortization	35,091	33,313
Adjustment to fair value of Connecticut forgivable loans	(7,748)	(75,936)
Realized and unrealized net investment (gains)/losses	(6,568)	6,753
Unrealized net (gains) on interest-rate swaps	(991)	(355)
Loss on disposal of long-lived assets	662	4,281
Contributions restricted for long-term investment and assets	(1,846)	(4,830)
Changes in actuarial assumptions	—	(490)
Changes in operating assets and liabilities	<u>(4,805)</u>	<u>(4,201)</u>
Net cash provided by operating activities	<u>60,156</u>	<u>52,176</u>
Cash flows from investing activities:		
Acquisition and construction of long-lived assets	(34,273)	(37,791)
Proceeds from investments	69,456	135,834
Purchases of investments	<u>(93,440)</u>	<u>(175,678)</u>
Net cash used in investing activities	<u>(58,257)</u>	<u>(77,635)</u>
Cash flows from financing activities:		
Repayment of bonds	(3,470)	(3,345)
Repayment of note payable	(101)	(130)
Decrease in funds held in escrow	326	7,048
Draws under Connecticut forgivable loans	4,727	14,232
Contributions restricted for long-term investment and assets	<u>1,846</u>	<u>4,830</u>
Net cash provided by financing activities	<u>3,328</u>	<u>22,635</u>
Net increase/(decrease) in cash and equivalents	5,227	(2,824)
Cash and equivalents, beginning of year	<u>4,375</u>	<u>7,199</u>
Cash and equivalents, end of year	\$ <u>9,602</u>	\$ <u>4,375</u>
Cash paid for interest	\$ 3,800	3,972

See accompanying notes to financial statements.

## THE JACKSON LABORATORY

Notes to Financial Statements

December 31, 2016 and 2015

### (1) Background

The Jackson Laboratory (the Laboratory) is a not-for-profit independent research organization focusing on research to advance human health. The purposes of the laboratory are scientific, medical, charitable, and educational. The Laboratory strives to discover precise genomic solutions for disease and empower the global biomedical community in its shared quest to improve human health. This mission is carried out through: (1) conducting basic biomedical research; (2) training and educating scientists worldwide; and (3) developing and providing scientific services, genetic resources, and genetic and clinical information related to genetic resources to the global scientific community.

### (2) Summary of Significant Accounting Policies

#### (a) Basis of Presentation

The Laboratory presents its financial statements on the accrual basis in accordance with U.S. generally accepted accounting principles (GAAP). All amounts presented in the notes to the financial statements are in thousands.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Management estimates requiring the application of significant judgment include Connecticut forgivable loans, obligations under postretirement plan, liabilities under self-insured plans, allowances for uncollectible receivables, valuations of interest-rate swaps, and certain alternative investments.

The Laboratory is a not-for-profit organization as described in Section 501(c)(3) of the Internal Revenue Code (the Code), as amended, and is generally exempt from income taxes pursuant to the Code. In accordance with GAAP, the Laboratory assesses whether there are uncertain tax positions and determined that there were no uncertain tax positions that would have a material effect on the financial statements.

#### (b) Classification of Net Assets

Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Subtopic 958-205, *Classification of Donor Restricted Endowment Funds Subject to an Enacted Version of the Uniform Prudent Management of Institutional Funds Act (ASC 958-205)*, provides guidance on the net asset classification of donor-restricted endowment funds, and requires comprehensive disclosures regarding both donor-restricted endowment funds and board-designated (quasi) endowment funds. The Laboratory is subject to the Maine Uniform Prudent Management of Institutional Funds Act (MUPMIFA) and, accordingly, classifies as temporarily restricted net assets the unappropriated and unspent balance above historic dollar value of its donor-restricted endowment funds. See note 5 for more information about the Laboratory's endowment.

## THE JACKSON LABORATORY

Notes to Financial Statements

December 31, 2016 and 2015

The financial statements have been prepared to focus on the Laboratory as a whole and to present balances and transactions according to the existence or absence of donor-imposed restrictions. Accordingly, net assets and changes therein are classified as follows:

- Unrestricted Net Assets – Net assets not subject to donor-imposed stipulations but which may be designated for specific purposes by the Laboratory’s Board of Trustees.
- Temporarily Restricted Net Assets – Net assets subject to donor-imposed stipulations that may or will be released upon actions of the Laboratory meeting the donor-imposed stipulations and/or the passage of time. In addition, unspent appreciation of donor-restricted endowment funds in excess of their historic dollar value is classified as temporarily restricted net assets until appropriated by the Laboratory and spent in accordance with the standard of prudence imposed by MUPMIFA.
- Permanently Restricted Net Assets – Net assets subject to donor-imposed stipulations that they be maintained in perpetuity. Generally, the donors permit the Laboratory to use all or part of the income earned and/or capital gains, if any, on related investments for general or specific purposes.

Revenue is reported as an increase in unrestricted net assets unless its use is limited by donor-imposed restrictions or it is a gift pledge or remainder trust and included in temporarily restricted revenue until collected. Expenditures of temporarily restricted funds are reported in the program where expended with the release of the restriction shown as a decrease in temporarily restricted net assets and an offsetting increase in unrestricted net assets.

### **(c) Revenue from Provision of Genetic Resources and Clinical and Research Services**

Revenue from providing genetic resources and clinical and research services is recognized when the resources are shipped or the services are provided and is included in Genetic Resources & Services revenue. Accounts receivable from such activities are reported net of allowance for uncollectible accounts.

### **(d) Revenue from Grants and Research Contracts**

The Laboratory recognizes revenue from grants and research contracts as related costs are incurred. Payments received in advance of expenditures are recorded as deferred revenue until expended. The Laboratory received approximately 73% and 73%, respectively, of its revenue from grants and contracts from the National Institutes of Health (NIH) for the years ended December 31, 2016 and 2015. Connecticut Innovations, Incorporated (CI) research and operating grant provided 19% and 18% of the grant revenue in 2016 and 2015, respectively. Indirect costs are billed and recovered in accordance with the terms of the grant and represented \$25,411 and \$28,676, respectively, of revenue from grants for the years ended December 31, 2016 and 2015. Most NIH grants reimburse for indirect costs at an agreed percentage of direct costs incurred. CI reimburses eligible costs up to an annual maximum amount. The Laboratory applies the CI grant funds to direct costs and then to indirect costs. The loss or significant reduction of Connecticut funding or federal programs could have a material adverse effect on the Laboratory’s operations. However, the Laboratory is not aware that any federal programs will be materially reduced. In addition, direct and indirect costs charged to federal programs are subject to audit and possible future adjustment. Management believes that the Laboratory is in compliance with applicable laws and regulations and that any possible adjustments would not be material to the financial statements.



**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

**(e) Revenue from Contributions**

Contributions, including unconditional promises to give, are recognized at fair value and increase net assets in the period received. Written promises to give that are scheduled to be received after the balance sheet date are shown as increases in temporarily restricted net assets and are reclassified to unrestricted net assets when the purpose or time restrictions are met. Promises to give subject to donor-imposed stipulations that the corpus be maintained permanently are recognized as increases in permanently restricted net assets. Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are substantially met. Contributions of cash and publicly traded securities are classified in Level 1 of the fair value hierarchy (see note 2(m)). Contributions of assets other than cash or publicly traded securities are recorded at their estimated fair value at the date of gift. As no market for future contributions exists, pledges are classified in Level 3 of the fair value hierarchy. Contributions to be received after one year are discounted at rates commensurate with the estimated risk of receipt of the pledge. Amortization of the discount is recorded as additional contribution revenue in the appropriate net asset category.

Contributions of cash or other assets that must be used to acquire long-lived assets or the contribution of long-lived assets are reported as temporarily restricted nonoperating support until the assets are acquired or placed in service.

Donor-directed changes made in subsequent periods to their original restrictions are reported as reclassifications between the applicable net asset classes.

**(f) Programmatic Expenses**

Expenses are presented on the statements of activities on a functional or programmatic basis, consisting of direct costs and indirect facility related costs. Facility-related expenses, including costs for the operation and maintenance of long-lived assets, financing costs and depreciation, are allocated on the basis of square footage utilized by each of the programs.

Expenses incurred by type for the years ended December 31, 2016 and 2015 are presented below:

Program	December 31, 2016				
	Research	Genetic resources and services	Training	Institutional support	Total
Salaries and wages	\$ 43,500	46,232	2,368	24,614	116,714
Benefits	13,424	14,267	731	7,596	36,018
Employee recruitment, training, memberships and subscriptions	1,283	394	32	3,396	5,105
Purchased services and stipends	10,276	4,762	1,191	6,353	22,582
Supplies and shipping	12,246	30,586	528	1,801	45,161
Maintenance, utilities and insurance	7,023	10,296	628	5,635	23,582
Travel and meals	1,559	2,564	792	1,713	6,628

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

December 31, 2016					
Program	Research	Genetic resources and services	Training	Institutional support	Total
Financing costs	\$ 1,899	3,013	91	371	5,374
Depreciation	16,792	15,119	1,133	2,422	35,466
Other expenses	43	2,337	94	1,204	3,678
Total	\$ <u>108,045</u>	<u>129,570</u>	<u>7,588</u>	<u>55,105</u>	<u>300,308</u>

December 31, 2015					
Program	Research	Genetic resources and services	Training	Institutional support	Total
Salaries and wages	\$ 43,453	44,747	2,247	24,246	114,693
Benefits	12,423	12,792	642	6,931	32,788
Employee recruitment, training, memberships and subscriptions	1,012	453	58	2,313	3,836
Purchased services and stipends	8,112	5,199	856	3,831	17,998
Supplies and shipping	11,107	26,267	425	2,819	40,618
Maintenance, utilities and insurance	6,783	10,173	427	6,109	23,492
Travel and meals	1,478	2,508	599	1,494	6,079
Financing costs	1,895	3,102	54	371	5,422
Depreciation	16,067	13,916	584	3,119	33,686
Other expenses	77	2,088	66	700	2,931
Total	\$ <u>102,407</u>	<u>121,245</u>	<u>5,958</u>	<u>51,933</u>	<u>281,543</u>

All direct and indirect costs of fundraising are expensed as incurred and are included in institutional support in the statements of activities. Direct fundraising expenses were \$3,033 and \$2,966 for the years ended December 31, 2016 and 2015, respectively.

**(g) Operating and Nonoperating Activities**

The statements of activities report changes in net assets from operating and nonoperating activities.

Operating activities consist of the Laboratory's ongoing research and training programs, including the provision of genetic resources and services. Included in operating revenue is investment return appropriated to support operations under the endowment income spending formula approved by the Board of Trustees, as described in note 5(b). Also included in operating revenue are research grant reimbursements of \$493 and \$171 for the years ended December 31, 2016 and 2015, for the purchase of equipment that became the property of the Laboratory upon acquisition. Depreciation charged to operating activities from research grant-funded equipment was \$1,368 and \$828 for the years ended December 31, 2016 and 2015, respectively.

## THE JACKSON LABORATORY

Notes to Financial Statements

December 31, 2016 and 2015

Nonoperating revenue includes items not related to the Laboratory's recurring activities or revenue that may not be used for operations. Accordingly, contributions for the acquisition of long-lived assets, net assets released from restrictions for the acquisition of long-lived assets, unrestricted bequests, investment return in excess of the amount appropriated under the Laboratory's spending formula, and grants to acquire land, buildings, and equipment are all reported as nonoperating activities. Changes in fair value of Connecticut forgivable loans and interest-rate swaps, as well as postretirement plan charges above periodic benefit costs, are also all presented as nonoperating activities.

### **(h) Cash and Equivalents**

For the purpose of the statement of cash flows the Laboratory considers cash equivalents as investments with maturities at date of purchase of three months or less.

### **(i) Self-Insurance Reserves**

The Laboratory is self-insured for worker's compensation claims for a portion of its worker's compensation program, and certain other healthcare benefits offered to active employees. These costs are accounted for on an accrual basis, which requires estimates to be made for claims incurred but not yet reported as of the balance sheet date.

### **(j) Long-Lived Assets**

Long-lived assets are reported at cost at date of acquisition or at fair value at date of donation in the case of gifts, which are classified in Level 3 of the fair value hierarchy. For assets placed in service, depreciation is provided using the straight-line method over the estimated useful lives of the assets. The cost of normal maintenance and repairs that does not add to the value of the asset or materially extend asset lives is not capitalized.

Depreciation is provided on a straight-line basis over the following estimated useful lives:

	<u>Years</u>
Buildings and improvements	15–50
Land improvements	5–15
Equipment and software	3–15

Management reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying value of a long-lived asset may not be recoverable. Management determined that no long lived assets were impaired as of December 31, 2016 and 2015.

The Laboratory receives awards from various granting agencies that allow for the purchase of certain assets, scientific equipment and construction of buildings. These assets are depreciated in accordance with the aforementioned policy. The assets become the property of the Laboratory upon acquisition, unless the grant or funding agreement specifically states otherwise. Grant-funded assets are typically restricted as to use and disposal.

## THE JACKSON LABORATORY

Notes to Financial Statements

December 31, 2016 and 2015

### **(k) Bonds and Notes Payable**

Forgivable loans are valued at fair value, reflecting the probability of forgiveness. All other debt is carried at cost.

Certain items related to the issuance of debt such as accounting, legal and auditing, as well as debt issuance costs and original issue discounts or premium are amortized over the period the related obligation is outstanding, generally using the interest method.

### **(l) Derivative Instruments**

The Laboratory utilizes interest-rate swap agreements with various counterparties to essentially convert its variable-rate debt to fixed rates and not for speculative purposes. The swaps' fair values and changes therein are recognized in the Laboratory's financial statements. Differences between the fixed and variable interest rates in effect are settled net monthly under each swap, increasing or decreasing interest expense. The estimated fair value of each swap is measured at each reporting date and presented as an asset (liability) based on the termination value as of that date using techniques such as discounted cash flow analysis and option pricing models that incorporate assumptions about future market interest rates. See footnote 8(d) for additional information on the interest rate swaps.

### **(m) Fair Value Measurements**

The Laboratory determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

- **Level 1 inputs:** Unadjusted quoted prices for identical assets or liabilities in active markets accessible to the entity at the measurement date.
- **Level 2 inputs:** Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
- **Level 3 inputs:** Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

The fair value hierarchy gives the highest priority to Level 1 inputs and the lowest priority to Level 3 inputs. In determining fair value, the Laboratory utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Levels are determined based on the aforementioned hierarchy, except for investments measured using net asset value (NAV) as a practical expedient to estimate fair value, as described in note 3.

It is the Laboratory's policy to review and reflect transfers between Levels as of the financial statement reporting date. Transfers between different levels of the fair value hierarchy are recorded as of the end of the reporting period.

The categorization of an investment within the fair value hierarchy is based on the inputs described above and does not necessarily correspond to the Laboratory's management's perceived risk of that investment. Moreover, the methods used by management may produce a fair value calculation that

## THE JACKSON LABORATORY

Notes to Financial Statements

December 31, 2016 and 2015

may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Laboratory believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments and nonfinancial assets and liabilities could result in a different fair value measurement at the reporting date.

### **(n) Fair Value of Financial Instruments**

The Laboratory discloses fair value information about all financial instruments, whether or not recognized in the balance sheets, for which it is practicable to estimate fair value. The Laboratory's financial instruments not carried at fair value are carried at net realizable value, which approximates fair value. Such financial instruments consist of cash equivalents, receivables from customers, and accounts payable and accrued expenses, which would be classified in Level 1 of the fair value hierarchy (excluding employee benefit obligations, which are not financial instruments).

### **(3) Investments**

#### **(a) Overall Investment Objective**

The overall investment objective of the Laboratory is to invest its long-term assets in a prudent manner that is intended to achieve a long-term rate of return sufficient to fund a portion of its annual operating activities and increase investment value after inflation. The investment objective for working capital investments is preservation of value and liquidity, relying on highly rated short-term interest-bearing investments. The Laboratory diversifies its long-term investments among various asset classes incorporating multiple strategies and managers. The Finance Committee, which oversees the Laboratory's investment program in accordance with Board of Trustee approved investment policy, relies on the Investment Subcommittee to recommend investment policy and implement the approved policy.

#### **(b) Investment Strategies**

The endowment is invested a manner that emphasizes the diversification of assets across categories of asset classes with differing sources of return and risk drivers. Fees are minimized through the use of indexed funds and direct purchases of short-term bonds and notes. The restricted assets may be invested with less liquidity and seek longer term returns through nonmarketable assets. The Laboratory may hold shares or units in institutional stock and fixed income funds as well as in alternative investment funds involving hedged strategies, private equity and real asset strategies. Funds with hedged strategies generally hold securities or other financial instruments for which a ready market exists and may include stocks, bonds, put or call options, swaps, currency hedges, credit default swaps and other instruments, and are valued accordingly. Private equity funds focus on investments not available in the public equity market. Real asset funds generally hold interests in commercial real estate, natural resources, or timber assets. Private equity and real asset strategies therefore often require the estimation of fair values by the fund managers in the absence of readily determinable market values. Because of the inherent uncertainties of valuation, these estimated fair values may differ significantly from values that would have been used had a ready market existed. Such valuations are determined by fund managers and generally consider variables such as operating results, comparable earnings multiples, projected cash flows, recent sales prices, and other pertinent information, and may reflect discounts for the illiquid nature of certain investments held.

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

**(c) Basis of Reporting**

Investments, including endowment and unrestricted operating investments are reported at estimated fair value. If an investment is held directly by the Laboratory and an active market with quoted prices exists, the market price of an identical security is used as the reported fair value. Reported fair values for shares in registered mutual funds are based on share prices reported by the funds as of the last business day of the fiscal year. The Laboratory's interests in commingled investment funds (multiple strategies) are generally reported at the net asset value (NAV) reported by the fund managers, which is used as a practical expedient to estimate the fair value of the Laboratory's interest therein, unless it is probable that all or a portion of the investment will be sold for an amount different from NAV.

**(d) Classification in the Fair Value Hierarchy**

The Laboratory owns interests in alternative investment funds rather than in the securities underlying each fund and has therefore applied the provisions of Accounting Standards Update (ASU) 2009-12, *Investments in Certain Entities that Calculate Net Asset Value (NAV) per Share (or its Equivalent)*. This standard allows for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable value using NAV per share or its equivalent as a practical expedient. The Laboratory has utilized the NAV reported by each of the underlying funds as a practical expedient to estimate the value of the investment. In 2016, the Laboratory retrospectively adopted ASU 2015-07, *Disclosures for Investments in Certain Entities that Calculate NAV per Share (or its Equivalent)*(ASU 2015-07), which clarified how investments valued using NAV as a practical expedient within the fair value hierarchy should be classified. ASU 2015-07 removes the requirement to classify within the fair value hierarchy table in Levels 2 or 3 investments in certain funds measured at NAV or its equivalent as a practical expedient to estimate fair value. The adoption did not impact the Laboratory's balance sheet, statement of activities, or statement of cash flows and resulted only in changes to the investment footnote disclosures.

The inputs or methodology used for valuing or classifying investments for financial reporting purposes are not necessarily an indication of the risk associated with investing in those investments or a reflection on the liquidity of each fund's underlying assets and liabilities.

There were no transfers between Level 1 and Level 2 for the fiscal years ended December 31, 2016 and 2015.

The following tables summarize the Laboratory's investments and other assets by major category in the fair value hierarchy as of December 31, 2016 and 2015, as well as related strategy, liquidity and funding commitments:

	December 31, 2016					
	Level 1	Level 2	NAV or equivalent	Total	Redemption or liquidation	Days' notice
Working capital investments:						
Money market accounts and certificates of deposit	\$ 31,621	—	—	31,621	Daily	One
U.S. government agency bonds	—	3,046	—	3,046	Daily	One

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

							December 31, 2016					
							Level 1	Level 2	NAV or equivalent	Total	Redemption or liquidation	Days' notice
Corporate bonds	\$	—	25,357	—	25,357	Daily	One					
U.S. and global fixed income funds		—	23,628	—	23,628	Daily	One					
Multiple strategies		107,431	—	—	107,431	Daily	One					
Total working capital investments		139,052	52,031	—	191,083							
Long-term investments (endowment):												
Money market accounts and certificates of deposit												
		2,089	—	—	2,089	Daily	One					
U.S. and global fixed income funds												
		27,307	—	—	27,307	Daily	One					
Equities:												
U.S. mid and large cap value funds												
		52,363	—	—	52,363	Daily	One					
Global large cap												
		26,345	—	—	26,345	Daily	One					
Global – developed markets												
		13,302	—	—	13,302	Daily	One					
Global – emerging markets												
		—	—	—	—	Daily	One					
Total equities		92,010	—	—	92,010							
Multiple hedged strategies												
		4,840	—	12,877	17,717	Daily to locked-up	One to n/a					
Private equity and real assets												
		—	—	3,632	3,632	Locked-up <sup>1</sup>	N/A					
Total long-term investments		126,246	—	16,509	142,755							
Total		\$ 265,298	52,031	16,509	333,838							

<sup>1</sup> The lock-up periods have various terms with extensions of one to two years. As of December 31, 2016, the average remaining life of these partnerships is approximately nine years.

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

	December 31, 2015					
	Level 1	Level 2	NAV or equivalent	Total	Redemption or liquidation	Days' notice
Working capital investments:						
Money market accounts and certificates of deposit	\$ 42,250	—	—	42,250	Daily	One
U.S. government agency bonds	—	8,398	—	8,398	Daily	One
Corporate bonds	—	38,430	—	38,430	Daily	One
U.S. and global fixed income funds	—	23,297	—	23,297	Daily	One
Multiple strategies	59,458	—	—	59,458	Daily	One
Total working capital investments	101,708	70,125	—	171,833		
Long-term investments (endowment):						
Money market accounts and certificates of deposit	3,880	—	—	3,880	Daily	One
U.S. and global fixed income funds	22,792	—	—	22,792	Daily	One
Equities:						
U.S. mid and large cap value funds	46,519	—	—	46,519	Daily	One
Global large cap	24,427	—	—	24,427	Daily	One
Global – developed markets	13,246	—	—	13,246	Daily	One
Global – emerging markets	778	—	—	778	Daily	One
Total equities	84,970	—	—	84,970		
Multiple hedged strategies	4,978	—	12,820	17,798	Daily to locked-up	One to n/a
Private equity and real assets	—	—	3,259	3,259	Locked-up <sup>1</sup>	N/A
Total long-term investments	116,620	—	16,079	132,699		
Total	\$ 218,328	70,125	16,079	304,532		

<sup>1</sup> The lock-up periods have various terms with extensions of one to two years. As of December 31, 2015, the average remaining life of these partnerships is approximately eight years.



**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

**(e) Commitments**

Private Equity investments are generally made through private limited partnerships. Under the terms of the partnership agreements, the Laboratory makes a commitment of a specific amount of capital to a partnership and is obligated to remit committed funding periodically when capital calls are exercised by the General Partner as the partnership executes on its investment strategy. Private equity funds are typically structured with investment periods of three-to-seven years. The aggregate amounts of unfunded commitments associated with private limited partnerships as of December 31, 2016 and 2015 were \$12,587 and \$3,370, respectively. The timing and amount of future capital calls expected to be exercised in any particular future year is uncertain.

Aggregate investment liquidity as of December 31, 2016 and 2015 is presented below based on redemption or sale period:

	<u>Investment fair values</u>	
	<u>2016</u>	<u>2015</u>
Investment redemption or sale period:		
Daily	\$ 317,329	288,453
Quarterly	4,909	10,047
Semi-annually to annually	7,402	1,651
Locked up	<u>4,198</u>	<u>4,381</u>
Total	<u>\$ 333,838</u>	<u>304,532</u>

**(4) Investment Return**

The following summarizes investment return for the years ended December 31, 2016 and 2015:

	<u>2016</u>	<u>2015</u>
Investment return:		
Interest and dividends	\$ 9,257	6,828
Realized net losses	(241)	(803)
Unrealized net gains/(losses)	<u>6,809</u>	<u>(5,950)</u>
Investment return	<u>\$ 15,825</u>	<u>75</u>

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

Investment returns are included in the statements of activities as follows for the years ended December 31, 2016 and 2015:

	<b>2016</b>	<b>2015</b>
Investment return:		
Operating:		
Long-term investment return utilized	\$ 980	548
Other investment return	7,874	801
Nonoperating activities:		
Long-term investment return above amounts utilized	6,971	(1,274)
Investment return	\$ 15,825	75

Investment return is net of bank and advisory fees, which were \$367 and \$394 for the years ended December 31, 2016 and 2015, respectively.

**(5) Endowment**

The Laboratory's endowment consisted of approximately 62 individual donor-restricted funds, as well as Board-designated funds held for the long-term support of the Laboratory's mission.

In 2016, the Board of Trustees set separate long-term investment return objectives and risk parameters for donor-restricted and Board-designated funds. For 2016 and 2015, donor-restricted funds were invested with an investment objective of a real total return of 5%. In contrast, Board-designated funds were invested with an investment objective of preserving value over the medium term while maintaining liquidity in the short term, defined as two years. The investment return objective is also an average annual real total return of 4%. Actual returns in any given year may vary from this amount.

**(a) Interpretation of Relevant Law**

The Laboratory classifies as permanently restricted net assets the original value of gifts made to establish donor-restricted endowment funds and any additions to such funds. The remaining portion of a donor-restricted endowment fund that is not classified as permanently restricted net assets is classified as temporarily restricted net assets until appropriated for expenditure by the Laboratory in a manner consistent with the standard of prudence prescribed by MUPMIFA.

**(b) Endowment Spending Policy**

Endowment net assets classified as unrestricted include funds designated by the Board as endowment (also referred to as quasi-endowment), including any accumulated return thereon. For donor-restricted endowment funds, the Laboratory follows the provisions of the Maine Uniform Prudent Management of Institutional Funds Act (MUPMIFA). The Laboratory reports as permanently restricted net assets an amount equal to the value of each permanent donor-restricted endowment fund at the time it became an endowment fund, and subsequent contributions and accumulations pursuant to the applicable gift instrument. Unless otherwise explicitly stipulated by the donor, return on investments in donor-restricted endowment funds is reported as temporarily restricted net assets until appropriated for expenditure by the Laboratory. The Laboratory considers several factors in making a determination to appropriate or accumulate donor-restricted endowment funds, including the individual endowment

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

fund's purpose, duration and preservation, the possible effect of inflation (or deflation), and expected total return.

**(c) Funds with Deficiencies**

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the historic dollar value of permanently restricted contributions. Deficiencies of this nature are reported in unrestricted net assets when they occur. Deficiencies totaled \$54 and \$124 at December 31, 2016 and 2015, respectively. Under MUPMIFA, spending from certain endowment funds with deficiencies as of December 31, 2016 is allowed for fiscal year 2017.

**(d) Endowment Activity**

The Laboratory's endowment consisted of the following at December 31, 2016 and 2015:

		<b>2016</b>			
		<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
	Donor-restricted	\$ (54)	33,578	17,462	50,986
	Board-designated	91,769	—	—	91,769
	Total	\$ 91,715	33,578	17,462	142,755
		<b>2015</b>			
		<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
	Donor-restricted	\$ (124)	32,565	15,947	48,388
	Board-designated	84,311	—	—	84,311
	Total	\$ 84,187	32,565	15,947	132,699

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

Changes in endowment assets for the years ended December 31, 2016 and 2015 are as follows:

	<b>December 31, 2016</b>			
	<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Endowment, December 31, 2015	\$ 84,187	32,565	15,947	132,699
Cash contributions	—	—	1,513	1,513
Board transfer from operating funds to endowment	1,500	—	—	1,500
Investment return	6,287	1,640	—	7,927
Long-term investment return utilized	—	(614)	—	(614)
Adjustment for underwater endowments	70	(70)	—	—
Net assets transferred per restrictions	—	(2)	2	—
In-transit transactions	(329)	59	—	(270)
Endowment, December 31, 2016	\$ <u>91,715</u>	<u>33,578</u>	<u>17,462</u>	<u>142,755</u>

	<b>December 31, 2015</b>			
	<b>Unrestricted</b>	<b>Temporarily restricted</b>	<b>Permanently restricted</b>	<b>Total</b>
Endowment, December 31, 2014	\$ 81,813	33,197	11,600	126,610
Cash contributions	—	—	4,349	4,349
Board transfer from operating funds to endowment	3,000	—	—	3,000
Investment return	(518)	(210)	—	(728)
Long-term investment return utilized	—	(548)	—	(548)
Adjustment for underwater endowments	(124)	124	—	—
Net assets transferred per restrictions	—	2	(2)	—
In-transit transactions	16	—	—	16
Endowment, December 31, 2015	\$ <u>84,187</u>	<u>32,565</u>	<u>15,947</u>	<u>132,699</u>

In-transit transactions are due to timing of transfers between the Laboratory's operational accounts and endowment accounts for gifts received and reimbursement of expenditures. Gifts are shown as the amount of cash received and therefore include the collection of pledge payments and exclude uncollected pledges.

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

**(6) Accounts Receivable**

Accounts receivable consisted of the following as of December 31, 2016 and 2015:

	<b>2016</b>	<b>2015</b>
Due from provision of genetic resources and services	\$ 25,225	26,675
Amounts reimbursable under grants and contracts	6,485	4,885
Miscellaneous accounts receivable	1,894	2,589
	33,604	34,149
Less allowance for uncollectibles	(865)	(1,161)
Accounts receivable, net	\$ 32,739	32,988

**(7) Long-Lived Assets**

Long-lived assets consisted of the following as of December 31, 2016 and 2015:

	<b>2016</b>	<b>2015</b>
Land and improvements	\$ 10,591	10,468
Buildings and improvements	506,449	501,560
Construction in progress	29,774	14,192
Equipment and software	144,202	131,175
	691,016	657,395
Less accumulated depreciation	(299,492)	(266,322)
Long-lived assets, net	\$ 391,524	391,073

The change in accounts payable for acquisition and construction of long-lived assets was an increase of \$2,303 and a decrease of (\$6,641) for the years ended December 31, 2016 and 2015, respectively.

Commitments to third parties for the purchase of equipment, space renovation and construction projects were \$29,596 and \$7,959 as of December 31, 2016 and 2015, respectively.

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

**(8) Bonds and Note Payable**

**(a) Bonds and Note Payable**

Bonds and note payable consisted of the following as of December 31, 2016 and 2015:

	<b>2016</b>	<b>2015</b>
Finance Authority of Maine Revenue Bonds (FAME Series 2012 Bonds)	\$ 35,155	37,075
Association of Bay Area Government for California fixed rate revenue bonds (ABAG Series 2012 bonds)	55,390	56,940
	90,545	94,015
Less unamortized discount	(180)	(192)
Plus unamortized premium	4,481	4,865
Debt issuance costs	(613)	(649)
Bonds payable, net	94,233	98,039
Note payable for real estate purchase	2,011	2,112
Bonds and note payable, net	\$ 96,244	100,151

The FAME Series 2012 bonds carry a variable interest rate and mature serially through July 1, 2031. A bank purchased the FAME Series 2012 bonds under a 10-year bond purchase agreement and supplemental letter agreement under which the Laboratory pays 67% of one-month LIBOR plus 1.02%. The agreements contain certain restrictive covenants, including meeting a semi-annual liquidity test, limits on incurring additional debt, and not allowing liens on property. Annually, in connection with providing the audited financial statements, the Laboratory may request an extension of the purchase agreement for up to nine additional years. In 2016, the Laboratory requested, and the bank granted a one year extension of the term of the original purchase agreement until 2026.

Should the financial institution holding the bonds under a direct purchase agreement accelerate the maturities of the obligation due to a subjective clause, under which conditions are not objectively determinable, the Laboratory would consider those obligations to be short-term in nature.

The Laboratory was in compliance with all financial covenants as of December 31, 2016 and 2015.

The ABAG Series 2012 bonds were issued with a par amount of \$60,290 and a premium of \$6,066 at fixed interest rates ranging from 2.5% to 5% over a 25-year term. The proceeds were used to refund existing ABAG bonds and fund the further fit-out of the Sacramento facility.

In connection with the purchase of property located contiguous to the Laboratory's Bar Harbor campus, the Laboratory entered into a \$2,260 fifteen year note with the seller of the property. The note bears a fixed interest rate of 4% and requires monthly mortgage amortization payments.

## THE JACKSON LABORATORY

Notes to Financial Statements

December 31, 2016 and 2015

### **(b) Connecticut Innovations, Incorporated Forgivable Loans**

On January 5, 2012, the Laboratory entered into several agreements with various sub-units of the state of Connecticut to build a 183,500 square foot laboratory and operate a genomics medicine research program in Farmington, Connecticut. The major agreements include a funding agreement with Connecticut Innovations, Incorporated (CI), a ground lease with the University of Connecticut Health Center (UCHC), and a collaboration agreement with the University of Connecticut (UConn).

The CI funding agreement provides a \$145,000 forgivable loan to construct a building and fit it out; a \$46,685 forgivable loan for the purchase of equipment over 10 years; and \$99,000 in grant commitments to support research and development over ten years. The loans will be forgiven if the Laboratory meets an employment goal of 300 employees for a period of six months, including a minimum of 90 senior scientists with an average wage exceeding a minimum target. In order for forgiveness to occur, the employment goal must be reached within ten years, or within the extended period if the Laboratory exercises an option to extend. The loans accrue simple interest at 1% per year, which is forgivable according to the same terms as the loans. If the Laboratory does not meet the employment goal, CI may elect that the Laboratory forfeit the building and equipment. In the event this election is made, the Laboratory reserves the right to lease the facility from CI for an initial period of five years, followed by an optional renewal period of five years. The loans are non-recourse to the Laboratory.

The Laboratory elected, under FASB ASC Topic 825, to report the forgivable loans at fair value. Therefore, the fair value of the loans is based on the probability that the Laboratory will meet the employment goals and the projected value of the underlying assets which collateralize the loans. An independent third-party valuation firm used a Monte Carlo simulation of key business plan assumptions to develop the fair value presented in the balance sheet. The difference between funds drawn through December 31 under the loans and the fair value is included in the nonoperating section of the statement of activities as an adjustment to fair value of Connecticut forgivable loans.

As part of the transaction, UCHC provided a 99-year ground lease for the building site. The ground lease contains a provision whereby the property will transfer to the Laboratory upon reaching 600 employees in Connecticut. The ground lease also includes limitations on the sale and use of the facility. A collaboration agreement with UConn covers joint faculty appointments, grant applications, UConn assignment and funding of faculty to be located at the Laboratory's Farmington site, and other related matters.

As of December 31, 2016 and 2015, the Laboratory had incurred \$152,139 and \$151,684, respectively, in project-related costs, which are included in construction in progress, buildings and improvements, and equipment. As of December 31, 2016 and 2015, the Laboratory had cumulatively received advances and accrued interest under the Connecticut forgivable loans of \$156,444 and \$150,205, respectively. The advances include \$0 and \$326 held in escrow by CI as retainage as of December 31, 2016 and 2015, respectively. The funds held in escrow are included in Funds Held in Escrow in the accompanying financial statements.

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

The following table summarizes the valuation techniques and significant unobservable inputs used by the Laboratory that are categorized within Level 3 of the fair value hierarchy as of December 31:

	<u>Fair value at December 31, 2016</u>	<u>Valuation technique</u>	<u>Unobservable inputs</u>	<u>Range (weighted average)</u>
Connecticut forgivable loans \$	5,760	Third-party valuation based on Monte Carlo simulations	Employee annual salaries by position	\$45–\$228 (\$80k)
			Employee annual salaries increases	1%–2.5% (1.7%)
			Employee benefits as a% of salaries	23.5%–26.5% (25%)
			Weighted case scenario probabilities	75%–90% (83.33%)
	<u>Fair value at December 31, 2015</u>	<u>Valuation technique</u>	<u>Unobservable inputs</u>	<u>Range (weighted average)</u>
Connecticut forgivable loans \$	7,270	Third-party valuation based on Monte Carlo simulations	Employee annual salaries by position	\$28–\$333 (\$153k)
			Employee annual salaries increases	1%–2.5% (1.7%)
			Employee benefits as a% of salaries	23.5%–26.5% (25%)
			Weighted case scenario probabilities	65%–90% (78.33%)

**(c) Maturities of Long-Term Debt**

Maturities of long-term debt as of December 31, 2016, were as follows:

	<u>Amounts due</u>
Year ending December 31:	
2017	\$ 3,727
2018	3,882
2019	4,043
2020	4,208
2021	4,389
Thereafter	<u>224,446</u>
Total	<u>\$ 244,695</u>



**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

Included in "Thereafter" in the above table is \$152,139 drawn through December 31, 2016 under the nonrecourse Connecticut loan agreements described in note 8(b). Such balance would be forgiven if the Laboratory meets certain employment goals as defined in the agreements.

**(d) Interest-Rate Swaps**

The Laboratory entered into interest-rate swap agreements, including forward-starting swaps, to essentially convert the variable rate on the \$37,075 of FAME borrowings outstanding to various fixed rates. The swaps' notional amounts amortize at the same rate as and cover the entire related debt principal throughout the term of the bonds, which mature in 2031.

Because the swap fair values are primarily based on observable inputs, such as the interest yield curve, that are corroborated by market data, the swap fair values are categorized as Level 2 in the fair value hierarchy. The estimated fair value shown in the financial statements is based on the estimated termination value as of the end of the year.

As of December 31, 2016 and 2015, the following interest-rate swap agreements were outstanding:

2016						
Counterparty	Issue date	Effective date	Expiration date	Remaining notional amount	Swap fixed rate	Fair value asset (liability)
1	6/12/2002	7/1/2002	7/1/2022	\$ 9,385	3.920 %	\$ (1,151)
2	6/11/2003	7/1/2003	7/1/2031	10,255	2.860	(1,076)
3	5/5/2005	7/1/2005	7/1/2031	6,130	3.271	(812)
4	6/20/2003	7/1/2012	7/1/2031	9,385	4.140	(1,865)
5*	6/20/2003	7/1/2022	7/1/2031	5,905	4.000	(559)
Totals						\$ <u>(5,463)</u>

\* As of December 31, 2016, represents a separate forward swap that effectively extends the initial swap expiration date through the related debt maturity date.

2015						
Counterparty	Issue date	Effective date	Expiration date	Remaining notional amount	Swap fixed rate	Fair value asset (liability)
1	6/12/2002	7/1/2002	7/1/2022	\$ 9,900	3.920 %	\$ (1,452)
2	6/11/2003	7/1/2003	7/1/2031	10,800	2.859	(1,297)
3	5/5/2005	7/1/2005	7/1/2031	6,475	3.271	(970)
4	6/20/2003	7/1/2012	7/1/2031	9,900	4.140	(2,181)
5*	6/20/2003	7/1/2022	7/1/2031	5,905	4.000	(554)
Totals						\$ <u>(6,454)</u>

\* As of December 31, 2015, represents a separate forward swap that effectively extends the initial swap expiration date through the related debt maturity date.

## THE JACKSON LABORATORY

Notes to Financial Statements

December 31, 2016 and 2015

The variable-rate side of the swaps is based on 67% of one-month LIBOR plus 1.02%. Swap agreements 3 and 4 contain a requirement for the Laboratory to post cash collateral if the aggregate mark-to-market value of the swaps exceeds a \$5,000 liability as of any month-end. Swap agreements 1, 2, and 5 contain a requirement for the Laboratory to post cash collateral if the aggregate mark-to-market value of the swaps exceed an \$8,000 liability as of any month end. The mark-to-market threshold amounts are exclusive. The counterparties are required to maintain a minimum credit rating as per the individual agreements.

Interest rate volatility, remaining outstanding principal and time to maturity will affect each swap's fair value at subsequent reporting dates. To the extent the Laboratory holds a swap through its expiration date, the swap's fair value will reach zero.

### **(9) Employee Benefits**

#### **(a) *Defined Contribution Retirement Plan and Other Benefits***

Subject to meeting certain eligibility requirements, all employees participate in a defined contribution 403(b) retirement plan administered by the Laboratory. Contribution expense was \$9,414 and \$8,685 for the years ended December 31, 2016 and 2015, respectively.

In addition, the Laboratory has supplemental pension obligations under employment agreements. The present value of the obligations is included in accrued expenses and is funded primarily through a split-interest life insurance arrangement. The cash value of the insurance policy is included in other assets. Life annuities were purchased to meet another obligation to provide additional retirement income. The cost of these annuities is included in other assets and is being amortized over the vesting period after which the annuity contracts transfer to the employee.

#### **(b) *Postretirement Medical Plan***

The Laboratory maintains a postretirement medical plan covering certain retired employees with hire dates before 2003 and faculty members eligible to retire on May 31, 2008, and their dependents. Other than the payment of current benefits totaling \$490 and \$489 in the years ended December 31, 2016 and 2015, respectively, the Laboratory has not funded the postretirement plan.

The impact of the changes in actuarial assumptions was a decrease in the liability resulting in a gain of \$880 and a loss of \$490 for the years ended December 31, 2016 and 2015, respectively, included in the nonoperating section of the statements of activities.

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

Benefit obligations and funded status of the plan for the years ended December 31, 2016 and 2015 were as follows:

	<b>Year ended December 31</b>	
	<b>2016</b>	<b>2015</b>
Changes in benefit obligations:		
Benefit obligation at beginning of year	\$ 5,659	6,329
Interest cost	235	239
Total actuarial (gain) loss	870	(372)
Medicare Part D subsidy with adjustment	47	(48)
Benefits paid, net of employee contributions	<u>(490)</u>	<u>(489)</u>
Benefit obligation at end of year	<u>6,321</u>	<u>5,659</u>
Changes in plan assets:		
Fair value of plan assets at beginning of year	—	—
Actual return on plan assets	—	—
Employer contributions	490	489
Employee contributions	52	52
Benefits paid	<u>(542)</u>	<u>(541)</u>
Fair value of plan assets at end of year	<u>—</u>	<u>—</u>
Accrued benefit cost recognized in the balance sheet	<u>\$ (6,321)</u>	<u>(5,659)</u>

Net periodic benefit cost consisted of the following components for the years ended December 31, 2016 and 2015:

	<b>Year ended December 31</b>	
	<b>2016</b>	<b>2015</b>
Interest cost	\$ 235	239
Medicare Part D subsidy	(73)	(61)
Amortization of net actuarial loss	<u>43</u>	<u>69</u>
Net periodic benefit cost recorded	<u>\$ 205</u>	<u>247</u>

The net loss and prior service credit for the postretirement plan that will be amortized into net periodic benefit cost in 2016 is \$43. The weighted average assumptions related to the discount rate used to determine benefit obligations for 2016 and 2015 were 3.66% and 3.69%, respectively.

The discount rates used to determine net periodic benefit cost for the years ended December 31, 2016 and 2015 were 3.69% and 3.42%, respectively.

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

The assumed health care cost trend rates at December 31, 2016 and 2015 were as follows:

	<u>2016</u>	<u>2015</u>
Healthcare cost trend rate assumed for next year	6.0 %	6.0 %
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)	3.8	3.8
Year that the rate reaches the ultimate trend rate	2076	2076

Assumed health care trend rates have a significant effect on the amounts reported for the health care plans. A one-percentage-point change in assumed health care cost trend rates would have the following effects:

	<u>One-point increase</u>	<u>One-point decrease</u>
Effect on total of service and interest cost	\$ 19	17
Effect on total on postretirement benefit obligation	620	535

The Laboratory's estimated future benefit payment obligation for the retiree medical benefit pension plan future benefit payment obligations are as follows:

	<u>Retiree medical benefits</u>
Year ending December 31:	
2017	\$ 434
2018	436
2019	434
2020	436
2021	436
2022 through 2026	2,106

**(c) Deferred Compensation Program**

The Laboratory maintains a nonqualified salary deferral plan (the 457(b) Plan) authorized under Section 457(b) of the Internal Revenue Code. The Laboratory holds an investment approximately matching the employee investment selections to assure funding is available to meet future liabilities. The liability at December 31, 2016 and 2015 was \$4,294 and \$3,792, respectively, and is included in accounts payable and accrued expenses. The investments valued at \$4,294 and \$3,792 as of December 31, 2016 and 2015, respectively, and are included in other assets.

The Laboratory also maintains a deferred compensation program under Section 457(f) of the Internal Revenue Code for management and certain highly compensated employees under which a portion of

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

the employee's compensation is deferred and vested over time. The liability of \$684 and \$430 at December 31, 2016 and 2015, respectively, is included in accounts payable and accrued expenses, and the corresponding assets are included in other assets.

**(10) Restricted Net Assets**

The Laboratory classifies gift pledges based on donor purpose restriction. Unrestricted pledges are shown as time restricted until collected.

**(a) Temporarily Restricted Net Assets**

Temporarily restricted net assets consisted of the following as of December 31, 2016 and 2015:

	<u>2016</u>	<u>2015</u>
Time-restricted	\$ 1,133	1,140
Unappropriated return on donor-restricted endowments	33,578	32,554
Restricted for acquisition and construction of long-lived assets	1,833	1,814
Restricted for research, training and other programs	<u>4,666</u>	<u>4,840</u>
	<u>\$ 41,210</u>	<u>40,348</u>

**(b) Permanently Restricted Net Assets**

Permanently restricted net assets consisted of the following as of December 31, 2016 and 2015:

	<u>2016</u>	<u>2015</u>
Research	\$ 13,343	11,890
Training	486	436
Other programs	865	853
General purposes	<u>2,768</u>	<u>2,768</u>
Total endowment	17,462	15,947
Pledges receivable	<u>2,718</u>	<u>2,449</u>
	<u>\$ 20,180</u>	<u>18,396</u>

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

**(c) Pledges Receivable and Remainder Trusts**

As of December 31, net assets restricted for the following purposes included outstanding pledges and remainder trusts, net of allowance for uncollectible pledges and time-value discounts:

	<u>2016</u>	<u>2015</u>
Time-restricted only	\$ 790	1,180
Restricted for acquisition or construction of long-lived assets	—	321
Restricted for research, training, and other programs	1,944	2,126
Permanently restricted	<u>2,718</u>	<u>2,449</u>
	<u>\$ 5,452</u>	<u>6,076</u>

**(d) Net Assets Released from Restrictions**

Net assets released from restrictions consisted of the following for the years ended December 31, 2016 and 2015:

	<u>Year ended December 31</u>	
	<u>2016</u>	<u>2015</u>
Operating activities:		
Research programs	\$ 1,045	821
Training programs	528	627
Other	137	66
Collection of unrestricted pledges	3	222
Transfer to permanently restricted	<u>2</u>	<u>2</u>
	<u>\$ 1,715</u>	<u>1,738</u>

**(11) Commitments and Contingencies**

**(a) Leases**

The Laboratory leases laboratory and office space and other equipment under leases accounted for as operating leases. Some of these leases have renewal options. Total rental expense was \$473 and \$96 for the years ended December 31, 2016 and 2015, respectively.

**THE JACKSON LABORATORY**

Notes to Financial Statements

December 31, 2016 and 2015

Estimated future minimum lease payments under noncancelable facility and equipment operating leases as of December 31, 2016 are as follows:

	<u>Amounts due</u>
Year ending December 31:	
2017	\$ 78
2018	<u>5</u>
Total	<u>\$ 83</u>

**(12) Legal Claims**

The Laboratory is subject to certain legal proceedings and claims that arise in the ordinary course of conducting its activities. While it is not possible to predict accurately or determine the eventual outcome of such actions, management believes that the outcome of proceedings will not have a material adverse effect on the Laboratory's financial position.

**(13) Related Party Transactions**

Members of the Laboratory's Board of Trustees and senior management may, from time to time, be associated, either directly or indirectly, with companies doing business with the Laboratory. The Laboratory has a written conflict of interest policy that requires, among other things, that no member of the Board of Trustees may participate in any decision in which he or she has a material financial interest.

Each trustee and member of management is required to certify compliance with the conflict of interest policy on an annual basis as well as disclose any potential related party transactions to the Audit Committee.

**(14) Subsequent Events**

The Laboratory has evaluated subsequent events from the balance sheet date of December 31, 2016 through May 12, 2017, the date on which the financial statements were issued, and determined there are no other items to disclose.